Do ERβ agonists like OSU-ERb-012 modulate T-lymphocyte activation and ameliorate left ventricular remodeling during chronic heart failure?
ERβ agonists such as OSU-ERb-012 show potential as selective immunomodulatory therapies to attenuate adverse left ventricular remodeling in chronic heart failure.
Our studies indicate that ERβ agonists and OSU-ERb-012, in particular, could be used as selective immunomodulatory drugs to inhibit CD4+ T cells during chronic HF.
Rosenzweig et al. (Wed,) studied this question.